Somewhat Favorable News Coverage Very Likely to Affect Oxford Immunotec Global PLC (OXFD) Stock Price

News headlines about Oxford Immunotec Global PLC (NASDAQ:OXFD) have been trending somewhat positive on Wednesday, according to AlphaOne Sentiment Analysis. AlphaOne, a service of Accern, rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Oxford Immunotec Global PLC earned a media sentiment score of 0.22 on AlphaOne’s scale. AlphaOne also gave news coverage about the company an impact score of 82 out of 100, indicating that recent news coverage is very likely to have an impact on the company’s share price in the next few days.

Several research analysts recently issued reports on OXFD shares. Zacks Investment Research raised Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, March 1st. BTIG Research reiterated a “buy” rating on shares of Oxford Immunotec Global PLC in a research note on Thursday, May 4th.

Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) opened at 14.12 on Wednesday. Oxford Immunotec Global PLC has a 1-year low of $7.73 and a 1-year high of $16.13. The firm’s 50-day moving average price is $14.91 and its 200 day moving average price is $14.56. The stock’s market cap is $323.72 million.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last announced its quarterly earnings results on Tuesday, May 2nd. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.01. Oxford Immunotec Global PLC had a negative net margin of 30.17% and a negative return on equity of 28.36%. The firm had revenue of $21.51 million during the quarter, compared to analyst estimates of $21.17 million. On average, equities analysts expect that Oxford Immunotec Global PLC will post ($1.09) earnings per share for the current fiscal year.

In related news, VP Elizabeth M. Keiley sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, March 20th. The shares were sold at an average price of $16.05, for a total transaction of $48,150.00. Following the transaction, the vice president now owns 25,429 shares in the company, valued at $408,135.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Peter Wrighton-Smith sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $15.43, for a total transaction of $462,900.00. Following the transaction, the chief executive officer now owns 491,668 shares in the company, valued at approximately $7,586,437.24. The disclosure for this sale can be found here. Insiders sold 89,000 shares of company stock worth $1,312,860 in the last 90 days. 7.58% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Very Likely to Affect Oxford Immunotec Global PLC (OXFD) Stock Price” was first published by BBNS and is owned by of BBNS. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/somewhat-favorable-media-coverage-very-likely-to-impact-oxford-immunotec-global-plc-oxfd-stock-price-updated/652005.html.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

12 Month Chart for NASDAQ:OXFD

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with our FREE daily email newsletter.

 


Latest News

David Price and Red Sox to Meet Following Rehab Start
David Price and Red Sox to Meet Following Rehab Start
Lack of Offense Leading to Mediocrity for Boston Red Sox
Lack of Offense Leading to Mediocrity for Boston Red Sox
MLB and Facebook Announce Live Streaming for Games
MLB and Facebook Announce Live Streaming for Games
Can Anyway Stop the Houston Astros?
Can Anyway Stop the Houston Astros?
Kevin Pillar Turns from Defense to Offense
Kevin Pillar Turns from Defense to Offense
Chris Iannetta Hit in Face with 93mph Fastball
Chris Iannetta Hit in Face with 93mph Fastball


Leave a Reply

 
© 2006-2017 BBNS.